Kringle Pharma, Inc.
Notice of Revisions to Earnings Guidance for the Fiscal Year Ending September 2026
Revised earnings forecast for the fiscal year ending September 2026. Revenue increased from the previous forecast of 332 million to 442 million yen; operating income improved from △1,018 million to △800 million; ordinary income from △1,018 million to △796 million; net income attributable to owners of parent from △1,020 million to △799 million, all revisions upward. The changes are due to revenue recognition from new contracts and timing differences in costs.
Key Figures
- Revenue: 442 million yen (previous forecast 332 million yen)
- Operating income: △800 million yen (previous forecast △1,018 million yen)
- Ordinary income: △796 million yen (previous forecast △1,018 million yen)
AI要約
Key points of earnings forecast revision
The revised earnings forecast for the fiscal year ending September 2026, announced today, increases revenue while improving most profit metrics by accounting for timing differences in costs. A transient revenue recognition of 1 hundred million yen from new contracts and timing mismatches in development costs are the primary factors driving the changes.
Outlook and risks
Actual results may differ from the revised forecast depending on contract execution status, market environment, and timing of development costs. Also, earnings per share are expected to improve due to changes in the number of shares outstanding during the period.
Clinglea Phama Co., Ltd.
Company overview · Stock price · Financial data · All IR
